Somewhat Favorable Press Coverage Somewhat Unlikely to Affect FibroGen (NASDAQ:FGEN) Share Price
Media stories about FibroGen (NASDAQ:FGEN) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. FibroGen earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.5169151735739 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Teachers Advisors, LLC Buys A Lot More FibroGen, Inc (FGEN) Stock In The Last Quarter – Modern Readers (modernreaders.com)
- FibroGen, Inc. (FGEN) registers a price change of -11.82% while Medovex Corporation (MDVX) – Stocks Gallery (stocksgallery.com)
- Insiders Selling, Short Interest Growing FibroGen, Inc (NASDAQ:FGEN) – Modern Readers (modernreaders.com)
- FibroGen, Inc (NASDAQ:FGEN) Insider K Peony Yu Sells 37,500 Shares (americanbankingnews.com)
- FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo Sells 95,000 Shares (americanbankingnews.com)
FGEN has been the subject of a number of recent research reports. Zacks Investment Research downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target for the company. in a research note on Friday, July 21st. BidaskClub raised FibroGen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Jefferies Group LLC initiated coverage on FibroGen in a research note on Monday, July 10th. They set a “buy” rating and a $50.00 price target for the company. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $48.00 price target on shares of FibroGen in a research note on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. FibroGen currently has an average rating of “Buy” and an average price target of $60.17.
FibroGen (FGEN) traded up 1.34% during midday trading on Friday, hitting $41.65. The stock had a trading volume of 1,005,368 shares. The stock has a 50-day moving average of $34.92 and a 200-day moving average of $28.29. The firm’s market cap is $2.97 billion. FibroGen has a 52 week low of $15.60 and a 52 week high of $51.70.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.01. The firm had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. Analysts forecast that FibroGen will post ($1.82) EPS for the current fiscal year.
In related news, VP Pat Cotroneo sold 95,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the sale, the vice president now owns 173,366 shares in the company, valued at $8,774,053.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider K Peony Yu sold 3,721 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $28.95, for a total value of $107,722.95. Following the sale, the insider now owns 221,507 shares in the company, valued at approximately $6,412,627.65. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 537,474 shares of company stock worth $19,220,138. Corporate insiders own 14.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-fibrogen-nasdaqfgen-share-price.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.